Huang BL, Chandra S, Shih DQ. Skin manifestations of inflamma⁃tory bowel disease[J]. Front Physiol, 2012, 3: 13. DOI: 10.3389/fphys.2012.00013.<br />
[4]
Ampuero J, Rojas⁃Feria M, Castro⁃Fernández M, et al. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease[J]. J Gastroenterol Hepatol, 2014, 29(2): 291⁃295. DOI: 10.1111/jgh.12352.<br />
Tolkachjov SN, Fahy AS, Wetter DA, et al. Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014[J]. J Am Acad Dermatol, 2015, 73(4): 615⁃622. DOI: 10.1016/j.jaad.2015.06.054.<br />
[7]
Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort[J]. Am J Gastroenterol, 2011, 106(1): 110⁃119. DOI: 10.1038/ajg.2010.343.<br />
[8]
Weizman A, Huang B, Berel D, et al. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients[J]. Inflamm Bowel Dis, 2014, 20(3): 525⁃533. DOI: 10.1097/01.MIB.0000442011.60285.68.